---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-006127"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:08:35.952757+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology raises $10M via private placement with CEO and Athyrium

## Summary
- Sold 3,584,228 shares at $2.79 each to CEO Alan Auerbach and an Athyrium fund for $10M gross proceeds.
- Each purchaser committed ~$5M; placement closed March 10, 2022, at closing price.
- Proceeds will be used for general corporate purposes; company to file resale registration statement within 135 days.
- Private placement exempt from registration under Section 4(a)(2) of Securities Act.
- CEO Auerbach participated alongside Athyrium, an existing noteholder affiliate.

## SEC filing metadata
- accession: 0001437749-22-006127
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774922006127/0001437749-22-006127-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774922006127/pbyi20220310_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-006127
- JSON: https://secwatch.observer/filing/0001437749-22-006127.json
- Plain text: https://secwatch.observer/filing/0001437749-22-006127.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.